



PRELIMINARY DRAFT

No. 3225

PREPARED BY
LEGISLATIVE SERVICES AGENCY
2012 GENERAL ASSEMBLY

DIGEST

Citations Affected: IC 12-7-2-1.8; IC 12-13-14-4.5; IC 12-15-35-28.

Synopsis: Cash assistance point of service and drug reports. Prohibits the distribution of cash assistance benefits at a point of sale terminal that is located on the premises of an adult entertainment establishment. Requires the drug utilization review board to prepare and submit a preferred drug list report to the select joint commission on Medicaid oversight one time per year. (Current law requires the report twice a year.)

Effective: July 1, 2012.



A BILL FOR AN ACT to amend the Indiana Code concerning human services.

Be it enacted by the General Assembly of the State of Indiana:

1 SECTION 1. IC 12-7-2-1.8 IS ADDED TO THE INDIANA CODE
2 AS A NEW SECTION TO READ AS FOLLOWS [EFFECTIVE JULY
3 1, 2012]: **Sec. 1.8. "Adult entertainment establishment", for**
4 **purposes of IC 12-13-14-4.5, means a place that provides**
5 **adult-oriented entertainment in which performers disrobe or**
6 **perform in an unclothed state for entertainment.**

7 SECTION 2. IC 12-13-14-4.5, AS AMENDED BY P.L.91-2006,
8 SECTION 10, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
9 JULY 1, 2012]: Sec. 4.5. (a) Except as provided in this section, the
10 division may distribute cash assistance benefits to a person who is
11 eligible for assistance under the Title IV-A assistance program through
12 an automated teller machine or a point of sale terminal that is
13 connected to the EBT system.

14 (b) The division may approve or deny participation in the EBT
15 system by a retailer that is not a food retailer.

16 (c) The division may not approve participation by a retailer or
17 financial institution in the EBT system for distribution of cash
18 assistance under the Title IV-A assistance program through an
19 automated teller machine or a point of sale terminal located on the
20 premises of any of the following:

21 (1) A horse racing establishment:

22 (A) where the pari-mutuel system of wagering is authorized;
23 and

24 (B) for which a permit is required under IC 4-31-5.

25 (2) A satellite facility:

26 (A) where wagering on horse racing is conducted; and

27 (B) for which a license is required under IC 4-31-5.5.

28 (3) An allowable event required to be licensed by the Indiana
29 gaming commission under IC 4-32.2.

30 (4) A riverboat or other facility required to be licensed by the
31 Indiana gaming commission under IC 4-33.



(5) A store or other establishment:

(A) where the primary business is the sale of firearms (as defined in IC 35-47-1-5); and

(B) that sells handguns for which a license to sell handguns is required under IC 35-47-2.

(6) A store or other establishment where the primary business is the sale of alcoholic beverages for which a permit is required under IC 7.1-3.

(7) An adult entertainment establishment.

(d) An establishment described in subsection (c)(1) through ~~(c)(6)~~ **(c)(7)** shall post a sign next to each automated teller machine or point of sale terminal located in the establishment informing a potential user that the automated teller machine or point of sale terminal may not be used to receive cash assistance benefits under the Title IV-A assistance program.

(e) An:

(1) establishment that does not post the sign required under subsection (d); or

(2) individual who attempts to use an automated teller machine or point of sale terminal **with a sign posted as required under subsection (d)** to access cash assistance benefits under the Title IV-A assistance program; ~~in violation of subsection (d);~~

commits a Class C misdemeanor.

(f) The division shall adopt rules under IC 4-22-2 to carry out this section.

SECTION 3. IC 12-15-35-28, AS AMENDED BY P.L.101-2005, SECTION 3, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE JULY 1, 2012]: Sec. 28. (a) The board has the following duties:

(1) The adoption of rules to carry out this chapter, in accordance with the provisions of IC 4-22-2 and subject to any office approval that is required by the federal Omnibus Budget Reconciliation Act of 1990 under Public Law 101-508 and its implementing regulations.

(2) The implementation of a Medicaid retrospective and prospective DUR program as outlined in this chapter, including the approval of software programs to be used by the pharmacist for prospective DUR and recommendations concerning the provisions of the contractual agreement between the state and any other entity that will be processing and reviewing Medicaid drug claims and profiles for the DUR program under this chapter.

(3) The development and application of the predetermined criteria and standards for appropriate prescribing to be used in retrospective and prospective DUR to ensure that such criteria and standards for appropriate prescribing are based on the compendia and developed with professional input with provisions for timely revisions and assessments as necessary.



(4) The development, selection, application, and assessment of interventions for physicians, pharmacists, and patients that are educational and not punitive in nature.

(5) The publication of an annual report that must be subject to public comment before issuance to the federal Department of Health and Human Services and to the Indiana legislative council by December 1 of each year. The report issued to the legislative council must be in an electronic format under IC 5-14-6.

(6) The development of a working agreement for the board to clarify the areas of responsibility with related boards or agencies, including the following:

(A) The Indiana board of pharmacy.

(B) The medical licensing board of Indiana.

(C) The SURS staff.

(7) The establishment of a grievance and appeals process for physicians or pharmacists under this chapter.

(8) The publication and dissemination of educational information to physicians and pharmacists regarding the board and the DUR program, including information on the following:

(A) Identifying and reducing the frequency of patterns of fraud, abuse, gross overuse, or inappropriate or medically unnecessary care among physicians, pharmacists, and recipients.

(B) Potential or actual severe or adverse reactions to drugs.

(C) Therapeutic appropriateness.

(D) Overutilization or underutilization.

(E) Appropriate use of generic drugs.

(F) Therapeutic duplication.

(G) Drug-disease contraindications.

(H) Drug-drug interactions.

(I) Incorrect drug dosage and duration of drug treatment.

(J) Drug allergy interactions.

(K) Clinical abuse and misuse.

(9) The adoption and implementation of procedures designed to ensure the confidentiality of any information collected, stored, retrieved, assessed, or analyzed by the board, staff to the board, or contractors to the DUR program that identifies individual physicians, pharmacists, or recipients.

(10) The implementation of additional drug utilization review with respect to drugs dispensed to residents of nursing facilities shall not be required if the nursing facility is in compliance with the drug regimen procedures under 410 IAC 16.2-3.1 and 42 CFR 483.60.

(11) The research, development, and approval of a preferred drug list for:

(A) Medicaid's fee for service program;



- 1 (B) Medicaid's primary care case management program;
- 2 (C) Medicaid's risk based managed care program, if the office
- 3 provides a prescription drug benefit and subject to IC 12-15-5;
- 4 and
- 5 (D) the children's health insurance program under IC 12-17.6;
- 6 in consultation with the therapeutics committee.
- 7 (12) The approval of the review and maintenance of the preferred
- 8 drug list at least two (2) times per year.
- 9 (13) The preparation and submission of a report concerning the
- 10 preferred drug list at least ~~two (2) times~~ **one (1) time** per year to
- 11 the select joint commission on Medicaid oversight established by
- 12 IC 2-5-26-3.
- 13 (14) The collection of data reflecting prescribing patterns related
- 14 to treatment of children diagnosed with attention deficit disorder
- 15 or attention deficit hyperactivity disorder.
- 16 (15) Advising the Indiana comprehensive health insurance
- 17 association established by IC 27-8-10-2.1 concerning
- 18 implementation of chronic disease management and
- 19 pharmaceutical management programs under IC 27-8-10-3.5.
- 20 (b) The board shall use the clinical expertise of the therapeutics
- 21 committee in developing a preferred drug list. The board shall also
- 22 consider expert testimony in the development of a preferred drug list.
- 23 (c) In researching and developing a preferred drug list under
- 24 subsection (a)(11), the board shall do the following:
- 25 (1) Use literature abstracting technology.
- 26 (2) Use commonly accepted guidance principles of disease
- 27 management.
- 28 (3) Develop therapeutic classifications for the preferred drug list.
- 29 (4) Give primary consideration to the clinical efficacy or
- 30 appropriateness of a particular drug in treating a specific medical
- 31 condition.
- 32 (5) Include in any cost effectiveness considerations the cost
- 33 implications of other components of the state's Medicaid program
- 34 and other state funded programs.
- 35 (d) Prior authorization is required for coverage under a program
- 36 described in subsection (a)(11) of a drug that is not included on the
- 37 preferred drug list.
- 38 (e) The board shall determine whether to include a single source
- 39 covered outpatient drug that is newly approved by the federal Food and
- 40 Drug Administration on the preferred drug list not later than sixty (60)
- 41 days after the date on which the manufacturer notifies the board in
- 42 writing of the drug's approval. However, if the board determines that
- 43 there is inadequate information about the drug available to the board
- 44 to make a determination, the board may have an additional sixty (60)
- 45 days to make a determination from the date that the board receives
- 46 adequate information to perform the board's review. Prior authorization



may not be automatically required for a single source drug that is newly approved by the federal Food and Drug Administration, and that is:

(1) in a therapeutic classification:

(A) that has not been reviewed by the board; and

(B) for which prior authorization is not required; or

(2) the sole drug in a new therapeutic classification that has not been reviewed by the board.

(f) The board may not exclude a drug from the preferred drug list based solely on price.

(g) The following requirements apply to a preferred drug list developed under subsection (a)(11):

(1) Except as provided by IC 12-15-35.5-3(b) and IC 12-15-35.5-3(c), the office or the board may require prior authorization for a drug that is included on the preferred drug list under the following circumstances:

(A) To override a prospective drug utilization review alert.

(B) To permit reimbursement for a medically necessary brand name drug that is subject to generic substitution under IC 16-42-22-10.

(C) To prevent fraud, abuse, waste, overutilization, or inappropriate utilization.

(D) To permit implementation of a disease management program.

(E) To implement other initiatives permitted by state or federal law.

(2) All drugs described in IC 12-15-35.5-3(b) must be included on the preferred drug list.

(3) The office may add a drug that has been approved by the federal Food and Drug Administration to the preferred drug list without prior approval from the board.

(4) The board may add a drug that has been approved by the federal Food and Drug Administration to the preferred drug list.

(h) At least ~~two (2) times~~ **one time** each year, the board shall provide a report to the select joint commission on Medicaid oversight established by IC 2-5-26-3. The report must contain the following information:

(1) The cost of administering the preferred drug list.

(2) Any increase in Medicaid physician, laboratory, or hospital costs or in other state funded programs as a result of the preferred drug list.

(3) The impact of the preferred drug list on the ability of a Medicaid recipient to obtain prescription drugs.

(4) The number of times prior authorization was requested, and the number of times prior authorization was:

(A) approved; and

(B) disapproved.



- 1 (i) The board shall provide the first report required under subsection
- 2 (h) not later than six (6) months after the board submits an initial
- 3 preferred drug list to the office.

